NASDAQ$OABI
OmniAb Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported financial results for the second quarter of 2023, highlighting advancements in business development and progress across partner programs.
OmniAb reported revenue of $6.9 million for the second quarter of 2023, a slight decrease compared to $7.2 million in the same period in 2022. The company's net loss for the quarter was $14.7 million, or $0.15 per share, compared to a net loss of $10.3 million, or $0.12 per share, for the same period in 2022. The company added four new partners and saw progress in partner programs, with two new programs entering the clinic.
- Revenue for the second quarter of 2023 was $6.9 million, compared to $7.2 million for the same period in 2022.
- Net loss for the second quarter of 2023 was $14.7 million, or $0.15 per share, compared with a net loss of $10.3 million, or $0.12 per share, for the same period in 2022.
- Four new license agreements were entered into, including with Merck & Co. and Neurocrine Biosciences Inc.
- Programs by OmniAb’s partners continued to progress during the quarter, including two entering the clinic.
Headline financials
Revenue & EPS history
OmniAb · Revenue · Quarterly
$6.95M
Revenue by segment
OmniAb · $6.95M total across 3 segments · Q2 2023
- License and Milestone$4.33M+86.2%62.3%
- Service Revenue$2.45M-48.2%35.3%
- Royalty Revenue$165K+18.7%2.4%
Forward guidance
The Company continues to expect its cash, cash equivalents and short-term investments balance at year-end 2023 to be slightly higher than year-end 2022. Current cash, cash equivalents and short-term investments, along with the cash OmniAb generates from operations, are expected to be sufficient to fund operations for the foreseeable future.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q2 2023
-2.1%
Avg return
Earnings day
+1.5%
Avg return
5 days after
+4.1%
Avg return
30 days after
39%
7 / 18 earnings
Positive
+9.9%
Q4 2025
Best reaction
-20.4%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.1% | +29.4% | +72.7% | |
| Q4 2025 | +9.9% | +9.9% | -14.9% | |
| Q3 2025 | -4.1% | +0.7% | +31.8% | |
| Q1 2025 | -7.2% | -3.2% | -4.5% | |
| Q4 2024 | -20.4% | -20.4% | -43.9% | |
| Q3 2024 | -11.5% | -15.7% | -13.0% | |
| Q2 2024 | +4.4% | +4.9% | -2.2% | |
| Q1 2024 | +3.1% | -0.9% | +2.2% | |
| Q4 2023 | -2.5% | +0.8% | -11.4% | |
| Q3 2023 | -6.8% | +3.5% | +7.3% | |
| Q2 2023 | -5.7% | -3.8% | -10.4% | |
| Q1 2023 | +6.1% | +16.1% | +37.3% | |
| Q4 2022 | +9.5% | +10.1% | +3.6% | |
| Q3 2022 | -15.5% | -4.1% | +19.3% | |
| Q2 2022 | +0.2% | +0.1% | +0.3% | |
| Q1 2022 | -0.0% | +0.0% | +0.1% | |
| Q4 2021 | -0.0% | -0.1% | -0.1% | |
| Q3 2021 | +0.0% | +0.0% | -0.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro